BRIEF RESEARCH REPORT article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
TREM-1 inhibitor specificity and timing of treatment initiation can impact its therapeutic efficacy in cancer and inflammatory disease
Provisionally accepted
- SignaBlok, Inc, Shrewsbury, Massachusetts, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Triggering receptor expressed on myeloid cells 1 (TREM-1) is a key regulator in inflammation and an emerging therapeutic target in oncology and inflammatory disease. Objective: This study aims to determine whether broad or macrophage-specific TREM-1 blockade demonstrates distinct therapeutic efficacy and superior outcomes in disease models. Methods: Ligand-independent TREM-1 inhibitory peptides GF9 and GA31 (the latter in a form of macrophage-targeted lipopeptide complexes, GA31-LPC) were evaluated in animal models of pancreatic cancer, sepsis, pulmonary inflammation, and fibrosis. GF9 inhibits TREM-1 on all TREM-1-expressing cells, while GA31-LPC targets TREM-1 predominantly on macrophages. Results: In fully immunocompetent mice, GF9 and GA31-LPC alone significantly inhibited pancreatic cancer progression. In combination with anti-PD-L1 therapy, GA31-LPC, but not GF9, overcame cancer resistance to PD-L1 checkpoint blockade and synergized with immunotherapy. In PANC-1 xenograft-bearing athymic nude mice, both GF9 and GA31-LPC increased complete response rate and survival when combined with chemotherapy. The effectiveness of these agents was dependent on the timing of treatment initiation. GF9 was effective only when given with but not after chemotherapy. In contrast, GA31-LPC was effective only when given after but not together with chemotherapy. Inhibitor specificity and treatment timing effects of therapeutic TREM-1 blockade were also observed in sepsis and acute lung injury models, but not in fibrosis. Conclusion: These findings for the first time demonstrate that both inhibitor specificity and timing of treatment initiation are crucial for therapeutic TREM-1 inhibition. This has significant implications for clinical strategies targeting TREM-1, particularly informing tailored treatment approaches for cancer and inflammatory diseases.
Keywords: TREM-1 inhibitory SCHOOL peptides , pan-TREM-1 blockade, macrophage-restricted TREM-1 blockade, resolution of inflammation, cancer therapy-induced inflammation, Acute and chronic inflammation diseases, Drug discovery & development, Pancreatic Cancer
Received: 20 Aug 2025; Accepted: 18 Nov 2025.
Copyright: © 2025 Sigalov. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Alexander B. Sigalov, sigalov@signablok.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.